Claudia Monaco

Claudia Monaco

Auto-generated profile, based on publicly available information

Claudia Monaco

University of Oxford

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MCMario Cibelli
Mario Cibelli
AFAntonio Rei Fidalgo
Antonio Rei Fidalgo
NTNiccolò Terrando
Niccolò Terrando
Daqing MaDaqing Ma
Daqing Ma
CMClaudia Monaco
Claudia Monaco
MMMervyn Maze
Mervyn Maze

23 November 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NTNiccolò Terrando
Niccolò Terrando
CMClaudia Monaco
Claudia Monaco
Daqing MaDaqing Ma
Daqing Ma
BFBrian M. J. Foxwell
Brian M. J. Foxwell
MFMarc Feldmann
Marc Feldmann
MMMervyn Maze
Mervyn Maze
Cognitive decline following surgery in older individuals is a major clinical problem of uncertain mechanism; a similar cognitive decline also follows severe infection, chemotherapy, or trauma and is currently without effective therapy. A variety of mechanisms have been proposed, and exploring the role of inflammation, we recently reported the role of IL-1β in the hippocampus after surgery in mice with postoperative cognitive dysfunction. Here, we show that TNF-α is upstream of IL-1 and provokes its production in the brain. Peripheral blockade of TNF-α is able to limit the release of IL-1 and prevent neuroinflammation and cognitive decline in a mouse model of surgery-induced cognitive decline. TNF-α appears to synergize withMyD88, the IL-1/TLR superfamily common signaling pathway, to sustain postoperative cognitive decline. Taken together, our results suggest a unique therapeutic potential for preemptive treatment with anti-TNF antibody to prevent surgery-induced cognitive decline.

19 November 2014 in International Immunology
Verified
Journal Article
Open access
PDF file
CMClaudia Monaco
Claudia Monaco
JNJagdeep Nanchahal
Jagdeep Nanchahal
PTPeter Taylor
Peter Taylor
MFMarc Feldmann
Marc Feldmann
While for a century therapeutics has been dominated by small molecules, i.e. organic chemicals of ~400Da absorbable via the gut, this is no longer the case. There are now a plethora of important medicines which are proteins and injectable, which have dramatically improved the therapy of many inflammatory diseases and of cancer. Most of these are monoclonal antibodies, some are receptor Ig Fc fusion proteins, others are cytokines or enzymes. The key to this new aspect of therapeutics has been the filling of unmet needs, and the consequent commercial success, which promoted further research and development. The first ‘biologic’ for a common disease, rheumatoid arthritis (RA), was a monoclonal antibody, infliximab, to human tumour necrosis factor (TNF). This was based on our work, which is described in this review, summarizing how TNF was defined as a good target in RA, how it was developed is described here, as well as future indications for anti-TNF and related agents. Biologics are now the fastest growing sector of therapeutics.

31 October 2011 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
NTNiccolò Terrando
Niccolò Terrando
LELars I. Eriksson
Lars I. Eriksson
JRJae Kyu Ryu
Jae Kyu Ryu
TYTing Yang
Ting Yang
CMClaudia Monaco
Claudia Monaco
MMMervyn Maze
Mervyn Maze

1 September 1996 in Circulation
Verified
Journal Article
Closed access
PDF file
LBLuigi M. Biasucci
Luigi M. Biasucci
AVAlessandra Vitelli
Alessandra Vitelli
GLGiovanna Liuzzo
Giovanna Liuzzo
SASergio Altamura
Sergio Altamura
GCGiuseppina Caligiuri
Giuseppina Caligiuri
AMAttilio Maseri
Attilio Maseri
Background Elevated plasma levels of C-reactive protein have been found in the majority of patients with unstable angina. The evidence of elevated levels of acute-phase proteins in unstable angina is in line with a growing body of evidence that suggests that inflammation plays a role in this syndrome and is an indirect sign of increased production of interleukin-6, which is the major determinant of acute-phase–protein production by the liver. However, in unstable angina, there is no direct proof of the role played by interleukin-6. Methods and Results We measured levels of interleukin-6 in 38 patients with unstable angina at the time of their admission to the coronary care unit and in 29 patients with stable angina. In the same groups of patients, we also measured C-reactive protein. Interleukin-6 (undetectable, ie, <3 pg/mL, in healthy volunteers) was detectable in 23 (61%) of 38 patients with unstable angina but in only 6 (21%) of 29 with stable angina ( P <.01). Median interleukin-6 levels were 5.25 pg/mL (range, 0 to 90 pg/mL) in patients with unstable angina but were below the detection limit of the assay in patients with stable angina (range, 0 to 7 pg/mL). A significant correlation was observed between interleukin-6 and C-reactive protein levels ( r =.4, P =.013). Conclusions Our study demonstrates that raised levels of interleukin-6 are common in unstable angina, correlate with C-reactive protein, and are associated with prognosis, thus confirming the importance of the cytokine pathway for the production by the liver of acute-phase proteins and strengthening the importance of inflammation in this syndrome. Further studies are required to elucidate better the role of interleukins in unstable angina.

17 September 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
BKBrenda Kwak
Brenda Kwak
MBMagnus Bäck
Magnus Bäck
MBMarie-Luce Bochaton-Piallat
Marie-Luce Bochaton-Piallat
GCGiuseppina Caligiuri
Giuseppina Caligiuri
MDMat J.A.P. Daemen
Mat J.A.P. Daemen
Paul EvansPaul Evans
Paul Evans
Blood vessels are exposed to multiple mechanical forces that are exerted on the vessel wall (radial, circumferential and longitudinal forces) or on the endothelial surface (shear stress). The stresses and strains experienced by arteries influence the initiation of atherosclerotic lesions, which develop at regions of arteries that are exposed to complex blood flow. In addition, plaque progression and eventually plaque rupture is influenced by a complex interaction between biological and mechanical factors—mechanical forces regulate the cellular and molecular composition of plaques and, conversely, the composition of plaques determines their ability to withstand mechanical load. A deeper understanding of these interactions is essential for designing new therapeutic strategies to prevent lesion development and promote plaque stabilization. Moreover, integrating clinical imaging techniques with finite element modelling techniques allows for detailed examination of local morphological and biomechanical characteristics of atherosclerotic lesions that may be of help in prediction of future events. In this ESC Position Paper on biomechanical factors in atherosclerosis, we summarize the current ‘state of the art’ on the interface between mechanical forces and atherosclerotic plaque biology and identify potential clinical applications and key questions for future research.